JDP Therapeutics Inc., based in Blue Bell, PA, is led by Jie Du, Ph.D., CEO and president. The company is advancing JDP-205, a proprietary injectable product being developed to treat acute allergic reactions in hospitals. Prior to the Series A, JDP-205 completed phase I and II clinical trials, held an end-of-phase-II FDA meeting, and secured FDA agreement on its pivotal phase III clinical protocol. JDP Therapeutics intends to use the new funding to advance JDP-205 through its pivotal phase III trial, and to support NDA filing and approval. The company has also secured a commercial supply agreement for JDP-205 with a major pharmaceutical company. The financing position provides capital to support late-stage development and regulatory milestones.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2016